Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             385 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 49 ABCB7 plays an essential role in sideroblast formation in acquired refractory anemia with ring sideroblasts Nikpour, M.
 2011
 35 S1 p. S17-S18
2 p.
 artikel
2 141 A case-control study to investigate risk factors for myelodysplastic syndromes in Southwestern Greece Avgerinou, C.
 2011
 35 S1 p. S54-S55
2 p.
 artikel
3 382 ACE-536, a modified activin receptor, prevents anemia in myelodysplastic syndromes Suragani, R.N.
 2011
 35 S1 p. S152-S153
2 p.
 artikel
4 Acknowledgements 2011
 35 S1 p. vi-
1 p.
 artikel
5 183 A comparative review of allogeneic stem cell transplantation for MDS/secondary AML versus de novo AML in Western Scotland Lund, K.
 2011
 35 S1 p. S72-
1 p.
 artikel
6 307 A comparison of clinical characteristics and the role of prognostic markers in 1757 MDS patients from Japan, Korea, and Germany Kuendgen, A.
 2011
 35 S1 p. S121-
1 p.
 artikel
7 91 A comparison of clinical findings between aplastic anemia and refractory cytopenia of childhood in 78 cases reviewed by central reviewers Hama, A.
 2011
 35 S1 p. S34-
1 p.
 artikel
8 374 Acute erythroid leukemia, a disease akin to myelodysplastic syndrome rather than acute myeloid leukemia Liu, C.-J.
 2011
 35 S1 p. S149-
1 p.
 artikel
9 25 Acute myeloid leukemia and hematopoietic lineage commitment Nerlov, C.
 2011
 35 S1 p. S9-
1 p.
 artikel
10 101 Age- and comorbidity-specific evaluation of azacitidine treatment, response and overall survival in 184 patients in the Austrian Azacitidine Registry Pleyer, L.
 2011
 35 S1 p. S38-S39
2 p.
 artikel
11 230 A genome-wide screen identifies frequently methylated genes in myelodysplastic syndrome Min, X.
 2011
 35 S1 p. S90-S91
2 p.
 artikel
12 83 Alemtuzumab induced – MDS or “the war of clones”? Braester, A.
 2011
 35 S1 p. S31-S32
2 p.
 artikel
13 30 Allogeneic stem cell transplantation from alternative stem cell sources in myelodysplastic syndromes Sanz, G.
 2011
 35 S1 p. S10-S11
2 p.
 artikel
14 66 Allogeneic stem-cell transplantation in chronic myelomonocytic leukemia (CMML): Factors affecting transplantation outcome. A study of the CLWP of the EBMT Symeonidis, A.
 2011
 35 S1 p. S25-
1 p.
 artikel
15 328 Allogeneic stem cell transplant for myelodysplastic syndromes: Results of 291 patients from Spanish MDS registry Campelo, M. Díez
 2011
 35 S1 p. S131-S132
2 p.
 artikel
16 248 Alterations of phenotype and gene expression during progression of myelodysplastic syndrome into acute myeloid leukemias Miyamoto, T.
 2011
 35 S1 p. S97-
1 p.
 artikel
17 217 A 12-month follow-up of an ongoing prospective, non-interventional, multicenter registry in iron overloaded patients with lower-risk myelodysplastic syndromes Garcia-Manero, G.
 2011
 35 S1 p. S85-
1 p.
 artikel
18 1 A mouse model highlights a role for p53 in 5q− syndrome Barlow, J.L.
 2011
 35 S1 p. S1-
1 p.
 artikel
19 169 A multicenter analysis of MDS diagnosis and treatment in daily clinical practice in Germany Gattermann, N.
 2011
 35 S1 p. S66-
1 p.
 artikel
20 153 Analysis of causes of death in 2297 patients with myelodysplastic syndromes. Data from the Dusseldorf MDS registry Nachtkamp, K.
 2011
 35 S1 p. S60-
1 p.
 artikel
21 321 Analysis of let-7a, mir-17 and mir-20a microRNA expression in CD34+ bone marrow cells of patients with myelodysplastic syndromes Vasilatou, D.
 2011
 35 S1 p. S128-
1 p.
 artikel
22 196 Analysis of the T-cell receptor Vδ and Vγ repertoire in the study of immunological abnormalities in myelodysplastic syndromes Geng, S.
 2011
 35 S1 p. S77-
1 p.
 artikel
23 93 Analysis of treatment choices and outcome for MDS and AML patients 60 years and older from the university of Dusseldorf Klärner, V.
 2011
 35 S1 p. S35-
1 p.
 artikel
24 361 An ambiguity of interpreting the diagnosis MDS with del(20q) Arakelyan, G.
 2011
 35 S1 p. S145-
1 p.
 artikel
25 104 An analysis of 101 cases of myelodysplastic syndrome in children Sheng, G.
 2011
 35 S1 p. S40-
1 p.
 artikel
26 381 A new point of view on myelodysplastic syndromes from a novel cooperative group in Italy (From: Gruppo Romano delle Mielodisplasie) Neri, B.
 2011
 35 S1 p. S152-
1 p.
 artikel
27 235 An integrative analysis of methylation and gene expression profiling in low-risk myelodysplastic syndromes (MDS) del Rev, M.
 2011
 35 S1 p. S92-S93
2 p.
 artikel
28 277 An observational study of treatment utilization and its variation by age in patients with MDS Henk, H.J.
 2011
 35 S1 p. S109-
1 p.
 artikel
29 255 A novel global DNA methylation detection by fluorescence spectroscopy, a possible evaluation system of demethylating status for myelodysplastic patients Ohyashiki, K.
 2011
 35 S1 p. S100-
1 p.
 artikel
30 318 A novel score optimized for accurate prediction of survival in patients with de novo myelodysplastic syndromes Sperr, W.R.
 2011
 35 S1 p. S127-
1 p.
 artikel
31 360 A novel t(17;22)(q12;q22) in a case of myelodysplastic syndrome characterized with signs of haemolytic anemia at presentation Antic, D.
 2011
 35 S1 p. S144-S145
2 p.
 artikel
32 162 A phase II study of decitabine in advanced chronic myelomonocytic leukemia (CMML) Braun, T.
 2011
 35 S1 p. S63-S64
2 p.
 artikel
33 114 A preliminary study on the application of diagnosis and prognosis of myelodysplastic syndromes by multiparametric flow cytometry immunophenotypic scoring system Huang, J.
 2011
 35 S1 p. S44-
1 p.
 artikel
34 138 A preliminary study on the value of periodic acid-Schiff stain in erythroblasts in myelodysplastic syndrome Xiao, Z.
 2011
 35 S1 p. S53-S54
2 p.
 artikel
35 373 A proposal of complementary classification in low risk myelodysplastic syndromes Duarte, F.B.
 2011
 35 S1 p. S148-S149
2 p.
 artikel
36 95 A “real life” experience with azacitidine: Comparing treatment adherence and tolerance with AZA-001 Lee, C.D.
 2011
 35 S1 p. S36-
1 p.
 artikel
37 250 Are Fli1, EKLF, PU.1, HDM2 and TP53 factors implicated in refractory anemia and megakaryopoiesis in 5q- syndrome? Neuwirtova, R.
 2011
 35 S1 p. S98-
1 p.
 artikel
38 178 A retrospective analysis of responses to decitabine in therapy-related MDS patients Klimek, V.M.
 2011
 35 S1 p. S70-
1 p.
 artikel
39 209 A retrospective analysis using 13- cis retinoic acid (13CRA) and alpha tocopherol (AT) in MDS patients to prevent progression Besa, E.C.
 2011
 35 S1 p. S82-
1 p.
 artikel
40 64 A retrospective time-dependent comparative analysis of the impact of lenalidomide on outcomes in lower risk MDS with chromosome 5q deletion Sanchez-Garcia, J.
 2011
 35 S1 p. S24-
1 p.
 artikel
41 124 Are we warranted to include patients with del 5q and trisomy 8 into the 5q minus syndrome? Neuwirtova, R.
 2011
 35 S1 p. S48-
1 p.
 artikel
42 254 Array based methylation analysis identifies DBC1, CDH1, DCC and WT1 as differentially methylated and prognostically relevant candidate genes in MDS Nowak, D.
 2011
 35 S1 p. S100-
1 p.
 artikel
43 78 A small subset of mesenchymal stem cells from MDS patients harbour the cytogenetic abnormality of haematopoietic cells Lopez-Villar, O.
 2011
 35 S1 p. S29-S30
2 p.
 artikel
44 371 Association between chronic liver disease and myelodysplastic syndrome: Report of three cases Gürkan, E.
 2011
 35 S1 p. S148-
1 p.
 artikel
45 68 ASXL1 is frequently mutated and associated with a negative prognosis in MDS Thol, F.
 2011
 35 S1 p. S25-S26
2 p.
 artikel
46 244 ASXL1 mutations are associated with distinct clinical features and poor outcome in myelodysplastic syndrome Hou, H.-A.
 2011
 35 S1 p. S95-S96
2 p.
 artikel
47 Author Index 2011
 35 S1 p. S155-S166
12 p.
 artikel
48 92 Autoimmune manifestations in chronic myelomonocytic leukemia Iastrebner, M.
 2011
 35 S1 p. S35-
1 p.
 artikel
49 216 Azacitidine low-dose schedule in low-risk myelodysplastic syndromes. Clinical results of a multicenter phase II study Fill, C.
 2011
 35 S1 p. S84-S85
2 p.
 artikel
50 170 Azacitidine plus entinostat: Results from E1905, the first randomized trial adding a histone deacetylase inhibitor to a DNMT inhibitor (DNMTi) Gore, S.
 2011
 35 S1 p. S66-S67
2 p.
 artikel
51 231 Azacitidine-resistant SKM1 MDS cells are defective for mitochondrial apoptosis and exhibit increased basal autophagy Cluzeau, T.
 2011
 35 S1 p. S91-
1 p.
 artikel
52 129 5-Azacytidine activates autophagy independently from disease status and the quality of achieved response Romano, A.
 2011
 35 S1 p. S50-
1 p.
 artikel
53 102 Azacytidine as a bridge to haploidentical bone marrow transplant in a patient with hypocellular myelodysplasia with monosomy 7 Rana, S.K.
 2011
 35 S1 p. S39-
1 p.
 artikel
54 128 5-Azacytidine induces STAT-5 activation through PLC-y1Tyr783 Romano, A.
 2011
 35 S1 p. S49-S50
2 p.
 artikel
55 172 Azacytidine in relapsed MDS and AML after allogeneic stem cell transplantation: Results of the French ATU Program Guièze, R.
 2011
 35 S1 p. S67-
1 p.
 artikel
56 161 Azacytidine 75mg/m2 ×5 day in high-risk myelodysplastic syndromes and acute myeloid leukemia refractory/relapsed patients: Results from a single centre Bergua, J.
 2011
 35 S1 p. S63-
1 p.
 artikel
57 202 B7-H1+ blasts in myelodysplastic syndromes: Morphological and genetic features and association with patient characteristics Kondo, A.
 2011
 35 S1 p. S79-
1 p.
 artikel
58 195 Biomarkers for response to lenalidomide (LEN) treatment in patients with myelodysplastic syndromes (MDS) Burbury, K.
 2011
 35 S1 p. S77-
1 p.
 artikel
59 351 Blood group antigen alloimmunization in patients with myelodysplastic syndromes Torres, R.
 2011
 35 S1 p. S140-S141
2 p.
 artikel
60 358 Case report: Melioidosis – six months after treatment with decitabine in MDS patient Rakpan, C.
 2011
 35 S1 p. S144-
1 p.
 artikel
61 85 Chacteristics and clinical features of 193 patients with myelodys-plastic syndromes: Experience of two centers from Turkey Ceneli, S.
 2011
 35 S1 p. S32-
1 p.
 artikel
62 380 Characterisation and targeting of malignant stem cells in myelodysplastic syndromes Chowdhury, O.
 2011
 35 S1 p. S152-
1 p.
 artikel
63 207 Characterization of FMNL1 expression in peripheral blood and bone marrow cells of MDS patients Lopes, M.R.
 2011
 35 S1 p. S81-
1 p.
 artikel
64 52 Chromatin structure at PU.l gene and cell differentiation capacity in myelodysplastic syndrome treated by 5-azacytidine Stopka, T.
 2011
 35 S1 p. S19-
1 p.
 artikel
65 132 Chromosomal abnormalities in primary myelodysplastic syndrome performed by conventional cytogenetics – tertiary care center experience Rashid, A.
 2011
 35 S1 p. S51-
1 p.
 artikel
66 47 Chromosomal complexity in primary myelodysplastic syndromes (MDS) in Nagasaki atomic bomb survivors Iwanaga, M.
 2011
 35 S1 p. S17-
1 p.
 artikel
67 298 Chromosome 7 abnormalities in MDS Gonzalez-Porras, J.R.
 2011
 35 S1 p. S117-S118
2 p.
 artikel
68 362 Chronic lymphocytic leukemia and myelodysplastic syndrome in a patient with intestinal carcinoma – a case report Mikulenkova, D.
 2011
 35 S1 p. S145-
1 p.
 artikel
69 150 Chronic myelomonocytic leukemia in the Southern Cone, Argentina's experience Iastrebner, M.
 2011
 35 S1 p. S58-S59
2 p.
 artikel
70 205 Circulating regulatory T cells (Tregs) in myelodysplastic syndromes (MDS) Statuto, T.
 2011
 35 S1 p. S80-
1 p.
 artikel
71 146 Claims-based prediction of performance status (PS) associated with erythropoietic-stimulating agent (ESA) treatment and survival in myelodysplastic syndromes (MDS) patients Ke, X.
 2011
 35 S1 p. S57-
1 p.
 artikel
72 226 Clinical analysis of 22 patients with non-del (5q) low- and intermediate-1-risk myelodysplastic syndrome treated with lenalidomide Yang, Y.
 2011
 35 S1 p. S89-
1 p.
 artikel
73 86 Clinical and prognostic relevance of isocitrate dehydrogenase 1 (IDH1) and IDH2 mutations in myelodysplastic syndrome Chen, T.C.
 2011
 35 S1 p. S32-S33
2 p.
 artikel
74 97 Clinical characteristics and survival of MDS patients in Hematology Clinic, University Hospital, Varna. Reassessment according to WHO, IPSS, WPSS Micheva, I.
 2011
 35 S1 p. S36-S37
2 p.
 artikel
75 152 Clinical characteristics of therapy-related myelodysplastic syndrome Kim, H.
 2011
 35 S1 p. S59-S60
2 p.
 artikel
76 359 Clinical complications in myelodysplastic syndromes Tendas, A.
 2011
 35 S1 p. S144-
1 p.
 artikel
77 300 Clinical features and prognostic factors of myelodysplastic syndrome in Taiwan Hou, H.-A.
 2011
 35 S1 p. S118-
1 p.
 artikel
78 313 Clinical features and prognostic significance of monosomal karyotype (MK) in the myelodysplastic syndromes (MDS) Nomdedeu, B.
 2011
 35 S1 p. S124-S125
2 p.
 artikel
79 61 Clinical impact of multiparameter flow cytometry in diagnosing myelodysplastic syndromes Kern, W.
 2011
 35 S1 p. S22-S23
2 p.
 artikel
80 304 Clinical impact of trisomy 11 in patients with MDS and AML Klärner, V.
 2011
 35 S1 p. S120-
1 p.
 artikel
81 98 Clinically meaningful responses in low risk MDS patients with del5q treated with lenalidomide: Quality of life and cardiac changes Oliva, E.
 2011
 35 S1 p. S37-
1 p.
 artikel
82 193 Clinical observation of HA-G regimen chemotherapy in remission induction for elderly patients with acute leukemia and myelodysplastic syndrome Wang, J.
 2011
 35 S1 p. S76-
1 p.
 artikel
83 331 Clinical outcomes of allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome: retrospective analysis of Fukuoka BMT group Kamimura, T.
 2011
 35 S1 p. S132-S133
2 p.
 artikel
84 376 Combination of deferasirox and deferoxamine for management of iron overload in myelodysplastic syndromes in hepatopathic patient: A case report Cerchione, C.
 2011
 35 S1 p. S150-
1 p.
 artikel
85 187 Combined sodium valproate and 5-azacitidine in the treatment of myelodysplastic syndrome Raghavan, M.
 2011
 35 S1 p. S74-
1 p.
 artikel
86 139 Combined use of internet and interactive sessions for cell morphology validation: experience and projects of the ELN WP10 Morphological Committee Zini, G.
 2011
 35 S1 p. S54-
1 p.
 artikel
87 107 Comparative analysis of flow cytometry indicators in myelodysplastic syndromes (MDS) and myeloproliferative disorders (MPD) Pepa, R. Delia
 2011
 35 S1 p. S41-
1 p.
 artikel
88 171 Complex effects of azacitidine in primary myelodysplastic and normal bone marrow cell cultures Grövdal, M.
 2011
 35 S1 p. S67-
1 p.
 artikel
89 118 Comprehensive genetic characterization of MDS patients by CD34+ bone marrow and peripheral blood combining FISH-, SNP- and chromosome banding analysis Ganster, C.
 2011
 35 S1 p. S45-S46
2 p.
 artikel
90 21 Conditioning regimen for allogeneic stem cell transplantation in MDS Kröger, N.
 2011
 35 S1 p. S8-
1 p.
 artikel
91 218 Continuous erythropoietin receptor activator in myelodysplastic syndromes (case report) Iastrebner, M.
 2011
 35 S1 p. S85-S86
2 p.
 artikel
92 99 Correlation between serum ferritin level at diagnosis and survival in lower risk, non-transfusion dependent, MDS patients Park, S.
 2011
 35 S1 p. S37-S38
2 p.
 artikel
93 275 Cost-effectiveness in Canada of azacitidine for the treatment of higher risk myelodysplastic syndromes and acute myeloid leukemia Zou, D.
 2011
 35 S1 p. S108-
1 p.
 artikel
94 343 Cost-effectiveness of deferasirox in lower-risk myelodysplastic syndrome (MDS) in Canada El Ouagari, K.
 2011
 35 S1 p. S137-S138
2 p.
 artikel
95 31 Cytogenetics – for how much longer? Schlegelberger, B.
 2011
 35 S1 p. S11-
1 p.
 artikel
96 117 Cytogenetic study of MDS Ganguly, B.
 2011
 35 S1 p. S45-
1 p.
 artikel
97 175 Czech MDS Group experience with azacitidine in treatment of high risk MDS and AML patients Jonasova, A.
 2011
 35 S1 p. S68-S69
2 p.
 artikel
98 184 Dacogen and allogeneic bone marrow transplantation in the treatment of high-risk myelodysplastic syndromes with non-random chromosome abnormalities Mamaev, N.
 2011
 35 S1 p. S72-S73
2 p.
 artikel
99 35 Debate: “Iron chelation therapy, as recommended in National MDS Management Guidelines, is an established standard of care” – contrarian position Steensma, D.P.
 2011
 35 S1 p. S12-
1 p.
 artikel
100 19 Debate: Lenalidomide is the standard of care for the management of isolated del 5(q) MDS Jadersten, M.
 2011
 35 S1 p. S7-S8
2 p.
 artikel
101 333 Decitabine with microtransplantation improves patient outcomes in myelodysplastic syndromes and secondary acute myeloid leukemia: short-term observation of a randomized study Sheng, A.H.
 2011
 35 S1 p. S133-
1 p.
 artikel
102 29 Deconstructing niche contributions to myelodysplasia in mice Raaijmakers, M.H.G.P.
 2011
 35 S1 p. S10-
1 p.
 artikel
103 339 Deferasirox treatment in myelodysplastic syndromes: “Real-life” efficacy and safety in a single institution patient population Breccia, M.
 2011
 35 S1 p. S136-
1 p.
 artikel
104 211 Deferasirox vs. deferiprone treatment in iron overloaded patients with myelodysplastic syndrome – a study on 113 patients with low-risk MDS Cermak, J.
 2011
 35 S1 p. S82-S83
2 p.
 artikel
105 310 Defining the role of novel genes and pathways in the progression of MDS to AML Liberante, F.G.
 2011
 35 S1 p. S122-
1 p.
 artikel
106 237 Detection and analysis of the DNA methylation in patients with myelodysplastic syndrome Wang, Y.
 2011
 35 S1 p. S93-
1 p.
 artikel
107 109 Development of a multiplex assay for rapid assessment of gene expression profiling of Rho GTPases family genes in MDS patients Shao, X.-J.
 2011
 35 S1 p. S42-
1 p.
 artikel
108 120 Diagnosing pedia trie bone marrow failures by objective myelodysplastic syndrome scoring system: A histopathological review Ito, M.
 2011
 35 S1 p. S46-
1 p.
 artikel
109 89 Diagnosis and management of Irish patients with myelodysplastic syndrome: data from the Irish National MDS Registry Enright, H.
 2011
 35 S1 p. S34-
1 p.
 artikel
110 126 Differences in patient characteristics between low-grade myelodysplastic syndromes and idiopathic cytopenia of uncertain significance Okuyama, N.
 2011
 35 S1 p. S49-
1 p.
 artikel
111 309 Different characteristics in younger or older patients with MDS, proposing disparity on pathogenesis? Li, X.
 2011
 35 S1 p. S122-
1 p.
 artikel
112 354 Disease burden and treatment impact associated with myelodysplastic syndromes: Initial estimates Demakos, E.
 2011
 35 S1 p. S142-
1 p.
 artikel
113 174 Does addition of erythropoietic stimulating agents (ESAs) improve the outcome of higher-risk MDS patients treated with azacitidine (AZA)? Itzykson, R.
 2011
 35 S1 p. S68-
1 p.
 artikel
114 176 Do genome scale methylation changes in patients with MDS treated with azacitidine and thalidomide correlate with response to treatment? Kenealy, M.
 2011
 35 S1 p. S69-
1 p.
 artikel
115 258 Down-regulation of DICER1, DROSHA and microRNAs in MSC from MDS compared to healthy controls Santamaría, C.
 2011
 35 S1 p. S101-
1 p.
 artikel
116 367 Durable response after lenalidomide discontinuation in del(5q) low risk MDS Comont, T.
 2011
 35 S1 p. S147-
1 p.
 artikel
117 20 Ectopic innate immune signaling in marrow cells results in an MDS phenotype Karsan, A.
 2011
 35 S1 p. S8-
1 p.
 artikel
118 240 Effect of azacitidine on inositide-dependent signalling pathways in low-risk MDS patients Follo, M.Y.
 2011
 35 S1 p. S94-
1 p.
 artikel
119 353 Effect of deferasirox on haemopoietic progenitor cells Vlachaki, E.
 2011
 35 S1 p. S141-S142
2 p.
 artikel
120 342 Effect of deferasirox on the immune response to invasive fungal infections in low risk MDS patients with iron overload Garcia, R.
 2011
 35 S1 p. S137-
1 p.
 artikel
121 348 Effect of iron chelators on labile iron and oxidative status in myelodysplastic syndrome (MDS) erythroid cells Prus, E.
 2011
 35 S1 p. S139-S140
2 p.
 artikel
122 284 Efficacy and toxicity of azacitidine 100 mg fixed dose for the treatment and re-treatment of myelodysplastic syndrome and acute myeloid leukemia Yeh, S.-P.
 2011
 35 S1 p. S111-S112
2 p.
 artikel
123 190 Efficacy of azacitidine and predictive factors for response in MDS and AML patients in the Dutch compassionate patient named programme van der Helm, L.
 2011
 35 S1 p. S75-
1 p.
 artikel
124 144 Epidemiology of myelodysplastic syndromes in the Republic of Armenia Daghbashyan, S.
 2011
 35 S1 p. S56-
1 p.
 artikel
125 246 Epigenetic promoter-methylation regulates mRNA expression of apoptosis-mediators in MDS Karlic, H.
 2011
 35 S1 p. S96-
1 p.
 artikel
126 203 ERK, p38 and NFκB involvement in the maturation defects of monocyte derived dendritic cells in patients with myelodysplastic syndrome Micheva, I.
 2011
 35 S1 p. S79-S80
2 p.
 artikel
127 145 Erythropoietic-stimulating agents (ESAs) are not associated with a transient risk of deep venous thrombosis (DVT) in myelodysplastic syndromes (MDS) Sato, M.
 2011
 35 S1 p. S56-S57
2 p.
 artikel
128 87 Erythropoietic-stimulating agents (ESAs) in the real world: do ESAs promote transfusion-independence (TI) in myelodysplastic syndrome (MDS) patients? Smith, S.R. Weiss
 2011
 35 S1 p. S33-
1 p.
 artikel
129 204 Erythropoietin-associated improved immune functions in MDS; dendritic cells as mediators Sagiv, S. Prutchi
 2011
 35 S1 p. S80-
1 p.
 artikel
130 337 Erythropoietin in patients with myelodysplastic syndrome of refractory anemia and refractory anemia with excess blasts-1 subtypes; efficacy and prognostic factors Bartzoudis, D.
 2011
 35 S1 p. S135-
1 p.
 artikel
131 308 Erythropoietin levels: More than just a marker of ESA response? Lee, C.D.
 2011
 35 S1 p. S121-
1 p.
 artikel
132 273 Erythropoietin plus danazole, prednisone, B12 and folate in refractory cytopenia with multilineage dysplasia (RCMD). Monocentric prospective study Giordano, G.
 2011
 35 S1 p. S107-
1 p.
 artikel
133 199 Evi1 and MDS1-Evi1 expression were related to the transformation of MDS Jiang, G.
 2011
 35 S1 p. S78-
1 p.
 artikel
134 94 Exercise-induced changes of pulmonary arterial pressure in patients with myelodysplastic syndromes Kqiku, X.
 2011
 35 S1 p. S35-
1 p.
 artikel
135 73 Expression of apoptosis associated genes in bone marrow cells from patients with myelodysplastic syndrome and acute myeloid leukemia Ilyenko, I.
 2011
 35 S1 p. S28-
1 p.
 artikel
136 77 Expression of γH2AX in myelodysplastic syndromes Kefala, M.
 2011
 35 S1 p. S29-
1 p.
 artikel
137 238 Expression of Herg mRNA in patients with myelodysplastic syndromes Geng, S.
 2011
 35 S1 p. S93-S94
2 p.
 artikel
138 74 Expression of TERT, TERF1 and TERF2 genes and telomere length in patients with myelodysplastic syndrome and acute myeloid leukemia Ilyenko, I.
 2011
 35 S1 p. S28-
1 p.
 artikel
139 163 Extra-medullary localization in high risk myelodysplastic syndromes: A new modality of relapse after therapy Comont, T.
 2011
 35 S1 p. S64-
1 p.
 artikel
140 224 Factors affecting leukemic transformation in patients with del-5q treated with lenalidomide Symeonidis, A.
 2011
 35 S1 p. S88-
1 p.
 artikel
141 282 Familial myelodysplastic syndrome/acute myeloid leukemia (MDS/AML): Report of 2 families Bastard, A. Stamatoullas
 2011
 35 S1 p. S111-
1 p.
 artikel
142 278 Familial myelodysplastic syndromes (MDS) in children associated with non-bone marrow failure congenital syndromes Makis, A.
 2011
 35 S1 p. S109-S110
2 p.
 artikel
143 44 FAS gene expression is epigenetically regulated and predicts the responsiveness to azacitidine in high-risk myelodysplastic syndromes Ettou, S.
 2011
 35 S1 p. S16-
1 p.
 artikel
144 82 Favourable outcome of young patient with t-MDS secondary to breast cancer treatment using azacitidine as induction therapy before allo-BMT Binotto, G.
 2011
 35 S1 p. S31-
1 p.
 artikel
145 113 Flow cytometric analysis of erythropoiesis: The last major frontier Cutler, J.A.
 2011
 35 S1 p. S43-S44
2 p.
 artikel
146 125 Flow cytometry contributes to distinguish between myelodysplastic syndromes and uncertain cytopenias Nikolova, V.
 2011
 35 S1 p. S48-S49
2 p.
 artikel
147 243 FLT3 and NPM1 mutations are rare molecular events in patients with de novo MDS and CMMoL Gritsaev, S.V.
 2011
 35 S1 p. S95-
1 p.
 artikel
148 110 Fluorescence in situ hybridization analysis has limited utility in myelodysplastic syndromes (MDS) cases with successful karyotyping Jiang, H.
 2011
 35 S1 p. S42-
1 p.
 artikel
149 131 Frequency of karyotype and FISH results in myelodysplastic syndromes: A single institutional experience Capetillo-Contreras, S.
 2011
 35 S1 p. S51-
1 p.
 artikel
150 4 Gene deletions and mutations in chronic myelomonocytic leukaemia Gelsi-Boyer, V.
 2011
 35 S1 p. S2-
1 p.
 artikel
151 223 Genetic monitoring of treatment response in the LE MON 5-study by classical cytogenetics and CD34-FISH on peripheral blood Shirneshan, K.
 2011
 35 S1 p. S87-S88
2 p.
 artikel
152 264 Genomic imbalances in 73 patients with MDS and complex karyotypes Zemanova, Z.
 2011
 35 S1 p. S104-
1 p.
 artikel
153 242 Genomics of myelodysplastic syndromes Graubert, T.
 2011
 35 S1 p. S95-
1 p.
 artikel
154 151 Geographical variation in diagnoses of myelodysplastic syndromes: Preliminary results of a prospective multinational non-interventional registry of anaemia patients (TORS) Ilhan, O.
 2011
 35 S1 p. S59-
1 p.
 artikel
155 10 Guidelines for immunosuppression in MDS Epling-Burnette, P.
 2011
 35 S1 p. S4-
1 p.
 artikel
156 155 Health-related quality of life by RBC transfusion dependence (TD) or independence (TI) of patients (Pts) initiating treatment for MDS Pashos, C.L.
 2011
 35 S1 p. S61-
1 p.
 artikel
157 34 Health-related quality of life in low-risk MDS patients from the European LeukemiaNet Registry: Correlation with age, gender and decreased survival Stauder, R.
 2011
 35 S1 p. S12-
1 p.
 artikel
158 180 Hematologic responses to flexible dosing of azacitidine in higher risk MDS/AML: 7 day therapy over an 8 day period Kumar, R.
 2011
 35 S1 p. S70-S71
2 p.
 artikel
159 366 Hematologic response to lenalidomide in myelodysplastic syndromes (MDS) with del(5q) and JAK2 V617F mutation Pepa, R. Della
 2011
 35 S1 p. S146-S147
2 p.
 artikel
160 37 Hematopoietic stem cells and leukemia in the niche Suda, T.
 2011
 35 S1 p. S13-
1 p.
 artikel
161 134 Hidden genomic abnormalities detected in MDS patients with a normal karyotype have prognostic relevance Royer-Pokora, B.
 2011
 35 S1 p. S52-
1 p.
 artikel
162 338 Home blood transfusions: feasibility and safety, three years of experience in myelodysplastic syndromes Boulanger, P.
 2011
 35 S1 p. S135-
1 p.
 artikel
163 346 Home care management of transfusions in patients with myelodysplastic syndromes Niscola, P.
 2011
 35 S1 p. S139-
1 p.
 artikel
164 57 How to assess the medullary blast count in MDS? Pay attention to the proportion of erythroid cells! Germing, U.
 2011
 35 S1 p. S20-S21
2 p.
 artikel
165 96 Hyperferritinemia in MDS patients – Polish MDS Registry results Dwilewicz-Trojaczek, J.
 2011
 35 S1 p. S36-
1 p.
 artikel
166 123 Hypocellular RAEB and hypocellular AML: Cytogenetic, immunophenotypic and morphological review of a six-year patient cohort from a regional diagnostic service Milic, M.
 2011
 35 S1 p. S47-S48
2 p.
 artikel
167 283 Hypomethylating agents improve the survival of myelodysplastic syndromes in a large population-based cohort Wang, R.
 2011
 35 S1 p. S111-
1 p.
 artikel
168 189 Hypomethylating agents induce apoptosis and cell cycle arrest with a concomitant activation of p53-dependent signalling pathways and Foxo3a activation Thepot, S.
 2011
 35 S1 p. S74-S75
2 p.
 artikel
169 69 Hypomethylation of a non-coding RNA on chromosome 5q31.1 is a positive prognostic factor for survival in AML/high risk MDS Treppendahl, M.B.
 2011
 35 S1 p. S26-
1 p.
 artikel
170 233 IER3 in childhood myelodysplastic syndrome de Vries, A.
 2011
 35 S1 p. S92-
1 p.
 artikel
171 115 ImageStream* quantitative analysis of cytomorphological and immunophenotypic erythroid cell lineage dyplasia in myelodysplastic syndromes Ouk-Martin, C.
 2011
 35 S1 p. S44-
1 p.
 artikel
172 261 Immunohistochemically detected p53 overexpression in bone marrow trephine biopsies discriminates del(5q) from other cytogenetic subtypes of myelodysplastic syndrome Trim, N.L.
 2011
 35 S1 p. S102-S103
2 p.
 artikel
173 121 Immunophenotyping in adults and children patients with myelodysplastic syndrome Maioli, C.
 2011
 35 S1 p. S46-S47
2 p.
 artikel
174 84 Impact of age and hemoglobin in MDS elderly patients' performance status Carbonell, A.L.
 2011
 35 S1 p. S32-
1 p.
 artikel
175 168 Impact of comorbidities in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) treated with azacitidine (AZA) Font, P.
 2011
 35 S1 p. S66-
1 p.
 artikel
176 306 Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias Kosmider, O.
 2011
 35 S1 p. S120-
1 p.
 artikel
177 157 Impact on quality of life of outpatient treatment in high risk myelodysplastic syndromes: Results of a pilot study Sekkaï, V.
 2011
 35 S1 p. S62-
1 p.
 artikel
178 265 Impaired hematopoietic stem cell function in Ssbp2 null mice: A possible role in 5q MDS Nagarajan, L.
 2011
 35 S1 p. S104-
1 p.
 artikel
179 340 Improvement in haematologic parameters in patients with MDS treated with the iron chelator deferasirox (Exjade®): An EPIC study post-hoc analysis Gattermann, N.
 2011
 35 S1 p. S136-S137
2 p.
 artikel
180 257 Inactivation of ICSBP by promoter methylation is likely involved in progressive leukemogenesis Otto, N.
 2011
 35 S1 p. S101-
1 p.
 artikel
181 140 Incidence of myelodysplastic syndromes in a well-defined population of Southwestern Greece Avgerinou, C.
 2011
 35 S1 p. S54-
1 p.
 artikel
182 81 Independent impact of transfusion dependency on overall survival and standardized mortality ratio of elderly patients with myelodysplastic syndromes Arnan, M.
 2011
 35 S1 p. S31-
1 p.
 artikel
183 55 Independent validation of the MDS Comorbidity Score (MDS-CI) Zipperer, E.
 2011
 35 S1 p. S20-
1 p.
 artikel
184 317 Influence of mild bone marrow fibrosis on response of int-2/high risk MDS patients to 5-azacitidine Sanna, A.
 2011
 35 S1 p. S126-S127
2 p.
 artikel
185 11 Informed patients are “better” patients Festy, P.
 2011
 35 S1 p. S4-S5
2 p.
 artikel
186 253 Insights on centromeric breakpoints of 5q deletions Nofrini, V.
 2011
 35 S1 p. S99-
1 p.
 artikel
187 58 Interaction of karyotype complexity and response on overall survival and AML progression in lenalidomide-treated Low/INT-1 risk del (5q) MDS patients Giagounidis, A.
 2011
 35 S1 p. S21-
1 p.
 artikel
188 23 International research activity in MDS – novel therapeutics List, A.
 2011
 35 S1 p. S9-
1 p.
 artikel
189 116 Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) by 2008 WHO classification Font, P.
 2011
 35 S1 p. S44-S45
2 p.
 artikel
190 186 Interstitial lung disease: Uncommon but potentially severe effect of hypomethylating agents Prévot, G.
 2011
 35 S1 p. S73-
1 p.
 artikel
191 341 Intravenous iron support vs oral liposomal iron support in patients with refractory anemia treated with Epo alpha. Monocentric prospective study Giordano, G.
 2011
 35 S1 p. S137-
1 p.
 artikel
192 15 Introduction to epigenetic regulation Grønbæk, K.
 2011
 35 S1 p. S6-
1 p.
 artikel
193 147 Involvement in treatment decisions, desire for prognostic information and quality of life in high-risk myelodysplastic syndromes: the physician's perspective Efficace, F.
 2011
 35 S1 p. S57-S58
2 p.
 artikel
194 375 Iron chelation therapy – case report Čeleketić, D.
 2011
 35 S1 p. S149-
1 p.
 artikel
195 208 Iron chelation therapy with deferasirox in transfusion dependent myelodysplastic syndrome patients. Preliminary report from the prospective MDS0306 GIMEMA trial Angelucci, E.
 2011
 35 S1 p. S81-S82
2 p.
 artikel
196 267 Iron overload accelerates deveopment of leukaemia in vivo Wells, R.A.
 2011
 35 S1 p. S105-
1 p.
 artikel
197 352 Iron overload in low-risk myelodysplastic syndromes (MDS): A multicentric study Improta, S.
 2011
 35 S1 p. S141-
1 p.
 artikel
198 256 IRS proteins in MDS and AML: A possible role of IRS2 in MDS erythroid cell differentiation Machado-Neto, J.
 2011
 35 S1 p. S100-S101
2 p.
 artikel
199 293 Is WPSS a good prognostic indicator for disease progression outcome? A 5-year retrospective study of 90 myelodysplastic patients Foucher, B.
 2011
 35 S1 p. S115-
1 p.
 artikel
200 26 Juvenile myelomonocytic leukemia: How many entities? Niemeyer, C.M.
 2011
 35 S1 p. S9-S10
2 p.
 artikel
201 228 Lenalidomide treatment of patients with 5q- syndrome affects genes located in the TNF pathway Belickova, M.
 2011
 35 S1 p. S89-S90
2 p.
 artikel
202 200 LOH and MSI of Mfd27 and 9P21 polymorphic microsatellite were related to the pathogenesis and transformation of MDS Jiang, G.
 2011
 35 S1 p. S78-
1 p.
 artikel
203 327 Long-term follow-up of intensive treatment in patients with high risk myelodysplastic syndromes (MDS) and secondary acute leukemia (sAML) Bargay, J.
 2011
 35 S1 p. S131-
1 p.
 artikel
204 219 Long-term outcome of anemic non del 5q lower-risk MDS refractory to or relapsing after erythropoiesis stimulating agents (ESAs) Kelaidi, C.
 2011
 35 S1 p. S86-
1 p.
 artikel
205 63 Long-term outcomes following RIC HSCT for MDS with fludarabine, busulphan and alemtuzumab Potter, V.
 2011
 35 S1 p. S23-
1 p.
 artikel
206 173 Low-dose cytarabine and homoharringtonine in combination with granulocyte colony-stimulating factor as treatment for patients with high-risk MDS – multicenter results from China He, G.
 2011
 35 S1 p. S68-
1 p.
 artikel
207 135 Lower bone marrow myeloid and plasmacytoid dendritic cell counts in high-risk than in low-risk MDS patients and controls Saft, L.
 2011
 35 S1 p. S52-
1 p.
 artikel
208 285 Low pre-treatment global methylation and day-15 marrow-blasts <45% but not WT1-expression correlate with response to azacitidine in AML Al-Ali, H.K.
 2011
 35 S1 p. S112-
1 p.
 artikel
209 214 Low risk MDS: 5-azacitidine, anything else? … Lenalidomide! De Miguel Llorente, D.
 2011
 35 S1 p. S83-S84
2 p.
 artikel
210 365 Low risk MDS – presenting as lead poisoning – with rapid transformation to acute leukemia – case report Cazaceanu, O.
 2011
 35 S1 p. S146-
1 p.
 artikel
211 349 Magnetic resonance imaging (MRI) detection of iron overload in patients with myelodysplastic syndrome (MDS) Santos, F.
 2011
 35 S1 p. S140-
1 p.
 artikel
212 377 Maintenance of normal serum ferritin in a patient with myelodysplastic/myeloproliferative disease-unclassifiable using deferasirox. A case report Gaman, M.
 2011
 35 S1 p. S150-
1 p.
 artikel
213 7 Management of 1000 patients with low- and intermediate-1 risk myelodysplastic syndromes in the European LeukemiaNet MDS Registry de Swart, L.
 2011
 35 S1 p. S3-
1 p.
 artikel
214 159 MDS in the young: Haematological features – a pilot study from India Tyagi, S.
 2011
 35 S1 p. S62-
1 p.
 artikel
215 292 MDS patients treated with 5-AZA in La Rioja (Spain): Results and application of the prognostic score proposed by Itzykson et al. Feliu, J.
 2011
 35 S1 p. S115-
1 p.
 artikel
216 17 MDS UK patient support group Hall, D.
 2011
 35 S1 p. S7-
1 p.
 artikel
217 269 Mechanisms of action of lenalidomide on erythroblastic islands in patients with low- or intermediate-1-risk MDS with del(5q) chromosome abnormality Buesche, G.
 2011
 35 S1 p. S106-
1 p.
 artikel
218 279 Methylation of Wnt antagonists and effects of AZA treatment on Wnt pathway in MDS cells Masala, E.
 2011
 35 S1 p. S110-
1 p.
 artikel
219 42 MicroRNA changes in patients with IPSS lower-risk myelodysplastic syndromes and del5q undergoing treatment with lenalidomide Cuzzola, M.
 2011
 35 S1 p. S15-
1 p.
 artikel
220 245 MicroRNA expression in MDS and MDS/MPN Hussein, K.
 2011
 35 S1 p. S96-
1 p.
 artikel
221 247 miRNA expression profiling in 5q- syndrome patients treated with lenalidomide Krejcik, Z.
 2011
 35 S1 p. S97-
1 p.
 artikel
222 266 Mitochondrial dysfunction enhances retention of hematopoietic stem cells in the HSC niche Andrzejewski, K.
 2011
 35 S1 p. S104-S105
2 p.
 artikel
223 251 MN1-ETV6 fusion gene and −7: an unusual karyotypic evolution in AML after MDS with 5q- Nofrini, V.
 2011
 35 S1 p. S98-S99
2 p.
 artikel
224 13 Molecular analysis as a diagnostic tool in myelodysplastic syndromes Graubert, T.
 2011
 35 S1 p. S5-
1 p.
 artikel
225 236 Molecular characterization of deletion of the long arm of chromosome 5 (del5q) in 86 MDS/AML patients Douet-Guilbert, N.
 2011
 35 S1 p. S93-
1 p.
 artikel
226 27 Molecular pathogenesis of the 5q- syndrome Pellagatti, A.
 2011
 35 S1 p. S10-
1 p.
 artikel
227 2 Morphological differentiation of hypocellular refractory cytopenia of childhood and severe aplastic anemia and clinical outcome Baumann, I.
 2011
 35 S1 p. S1-
1 p.
 artikel
228 378 Morphological differentiation of hypocellular refractory cytopenia of childhood and severe aplastic anemia and clinical outcome Baumann, I.
 2011
 35 S1 p. S151-
1 p.
 artikel
229 272 Morphologic and phenotypic characterization of paediatric secondary acute myeloid leukemia (sAML) Francescato, S.
 2011
 35 S1 p. S107-
1 p.
 artikel
230 3 Morphologic criteria for defining granulocytic dysplasia in MDS Goasguen, J.E.
 2011
 35 S1 p. S2-
1 p.
 artikel
231 12 Morphology is dead – long live morphology Germing, U.
 2011
 35 S1 p. S5-
1 p.
 artikel
232 316 Multiparametric flow cytometry is able to disclose features predictive for disease progression in MDS Reis-Alves, S.C.
 2011
 35 S1 p. S126-
1 p.
 artikel
233 369 Multiple myeloma and low risk MDS. Unique treatment: Lenalidomide De Miguel Llorente, D.
 2011
 35 S1 p. S147-
1 p.
 artikel
234 260 Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes RUNX1/AML1 lesions Quentin, S.
 2011
 35 S1 p. S102-
1 p.
 artikel
235 350 Myelodysplastic syndrome and alloimmunization: The impact of prophylactic Rh and Kell matching for red cell transfusion Sholzberg, M.
 2011
 35 S1 p. S140-
1 p.
 artikel
236 364 Myelodysplastic syndrome. Egyptian experience Mattar, M.
 2011
 35 S1 p. S146-
1 p.
 artikel
237 158 Myelodysplastic syndrome in the young age group in Hungary Timar, B.
 2011
 35 S1 p. S62-
1 p.
 artikel
238 148 Myelodysplastic syndrome in very elderly patients: practice in the real life. Preliminary results on a monocentric cohort Gourin, M.-P.
 2011
 35 S1 p. S58-
1 p.
 artikel
239 142 Myelodysplastic syndrome patients younger than 50 years: Epidemiological data and clinical features Breccia, M.
 2011
 35 S1 p. S55-
1 p.
 artikel
240 80 Myelodysplastic syndromes and pure red cell aplasia with del(5q) Cerciello, G.
 2011
 35 S1 p. S30-S31
2 p.
 artikel
241 370 Myelodysplastic syndromes in children – Bosnian aspects Bajraktarevic, A.
 2011
 35 S1 p. S147-S148
2 p.
 artikel
242 149 Myelodysplastic syndromes (MDS) and iron overload (screening data of 289 patients with de novo MDS) Gritsaev, S.V.
 2011
 35 S1 p. S58-
1 p.
 artikel
243 59 Myelodysplastic syndromes with isolated neutropenia or thrombocytopenia: Are they refractory cytopenias with unilineage dysplasia? A GFM registry study Gyan, E.
 2011
 35 S1 p. S22-
1 p.
 artikel
244 39 Myeloid-derived suppressor cells (MDSC) are effectors of bone marrow suppression in lower risk myelodysplastic syndromes (MDS) Wei, S.
 2011
 35 S1 p. S13-
1 p.
 artikel
245 156 National Argentine Registry of Myelodysplastic Syndrome in recently diagnosed adult patients Prates, M.V.
 2011
 35 S1 p. S61-
1 p.
 artikel
246 271 Nerve growth factor receptor/p75(NGFR)+ mesenchymal stromal cells are in contact with CD34+ progenitors and are increased in myeloid neoplasia Flores-Figueroa, E.
 2011
 35 S1 p. S106-S107
2 p.
 artikel
247 6 New mutations in MDS/MPN Cross, N.C.P.
 2011
 35 S1 p. S2-S3
2 p.
 artikel
248 24 New prognostic scores Malcovati, L.
 2011
 35 S1 p. S9-
1 p.
 artikel
249 48 Next-generation sequencing technology combined with multiplexed barcoded samples of myelodysplastic syndromes reveals an abundance of target gene mutations Nagata, Y.
 2011
 35 S1 p. S17-
1 p.
 artikel
250 239 NF-κB regulates FAS gene expression in myelodysplastic syndromes Ettou, S.
 2011
 35 S1 p. S94-
1 p.
 artikel
251 46 Novel role of p15Ink4b tumor suppressor in erythropoiesis and hematopoietic homeostasis Humeniuk, R.
 2011
 35 S1 p. S16-S17
2 p.
 artikel
252 227 NPM1 gene abnormalities in myelodysplastic syndromes with long arm chromosome 5 deletion Ammatuna, E.
 2011
 35 S1 p. S89-
1 p.
 artikel
253 252 NPM1 haploinsufficiency in human myeloid diseases with non-isolated −5/5q- Nofrini, V.
 2011
 35 S1 p. S99-
1 p.
 artikel
254 221 Occurrence of trisomy 8 (+8) in patients with Low- or Int-1-risk MDS with deletion 5q [del(5q)] treated with lenalidomide Mufti, G.
 2011
 35 S1 p. S87-
1 p.
 artikel
255 33 Optimising combination strategies Sekeres, M.A.
 2011
 35 S1 p. S11-S12
2 p.
 artikel
256 28 Optimising pre and post transplant management Platzbecker, U.
 2011
 35 S1 p. S10-
1 p.
 artikel
257 181 Oral azacitidine is bioavailable and reduces DNA methylation at low doses in extended schedules: Phase I study results Laille, E.
 2011
 35 S1 p. S71-
1 p.
 artikel
258 276 Outcome of azacitidine treatment of patients with therapy related myelodysplastic syndrome Komrokji, R.S.
 2011
 35 S1 p. S108-S109
2 p.
 artikel
259 105 Outcome of high risk myelodysplastic syndrome after azacytidine failure Prebet, T.
 2011
 35 S1 p. S40-
1 p.
 artikel
260 332 Outcomes of reduced intensity conditioning HSCT for lower-risk MDS: King's college hospital experience Pinto, R.
 2011
 35 S1 p. S133-
1 p.
 artikel
261 100 Overall survival data of patients with MDS, AML and CMML from the Austrian Azacitidine Registry of 184 consecutive patients Pleyer, L.
 2011
 35 S1 p. S38-
1 p.
 artikel
262 70 Overexpression of pFAK in myelodysplastic mesenchymal stromal cells correlates with tumor aggressive phenotype and with a decreased hematopoietic clonogenic capacity Aanei, C.
 2011
 35 S1 p. S27-
1 p.
 artikel
263 71 Pathogenetic and prognostic role of vascular endothelial growth factor in myelodysplastic syndromes Bellistri, F.
 2011
 35 S1 p. S27-
1 p.
 artikel
264 32 Patient-doctor relationship – perceptions Sekeres, M.A.
 2011
 35 S1 p. S11-
1 p.
 artikel
265 197 Patients with early stage myelodysplastic syndromes show increased frequency of CD4+CD25high+CD127low regulatory T-cells Fozza, C.
 2011
 35 S1 p. S77-S78
2 p.
 artikel
266 90 Pediatric myelodysplastic syndromes – a developing countries perspective George, B.
 2011
 35 S1 p. S34-
1 p.
 artikel
267 179 Phase 1/2 study of decitabine in combination with tretinoin in myelodysplastic syndromes: Interim results Klimek, V.M.
 2011
 35 S1 p. S70-
1 p.
 artikel
268 194 Phenotypical and functional characterization of mesenchymal stem cells derived from patients affected by Shwachman-Diamond syndrome André, V.
 2011
 35 S1 p. S76-S77
2 p.
 artikel
269 280 PI3K/AKT pathway is involved in myelodysplastic syndrome progression Rezende, D.C.
 2011
 35 S1 p. S110-
1 p.
 artikel
270 288 Point mutations in myelodysplastic syndromes: Associations with clinical features and independent predictors of overall survival Bejar, R.
 2011
 35 S1 p. S113-
1 p.
 artikel
271 229 Polycomb group protein BMI1 in leukemia development and progression: blocking the cell differentiation Shen, H.-J.
 2011
 35 S1 p. S90-
1 p.
 artikel
272 182 Preliminary safety analysis of an expanded access program for decitabine in subjects with myelodysplastic syndrome from Brazil and Asia Purushothaman, V.
 2011
 35 S1 p. S72-
1 p.
 artikel
273 335 Pre-transplant disease progression following hypomethylating treatment predicts higher relapse after stem cell transplantation for myelodysplastic syndromes Yahng, S.A.
 2011
 35 S1 p. S134-
1 p.
 artikel
274 326 Pre-transplant serum ferritin and marrow donor CD34+-cell-chimerism day 28 correlate with outcome after allogeneic hematopoietic transplantation following reduced-intensity-conditioning in MDS Al-Ali, H.
 2011
 35 S1 p. S130-S131
2 p.
 artikel
275 330 Pretransplant use of decitabine as a bridging therapy for myelodysplastic syndrome Jang, J.H.
 2011
 35 S1 p. S132-
1 p.
 artikel
276 262 PRF1 promoter hypomethylation in CD4+ T lymphocytes from patients with 5q- syndrome is restored after lenalidomide treatment Guerra, A.
 2011
 35 S1 p. S103-
1 p.
 artikel
277 41 Profiling and characterizing aberrant DNA and histone methylations of lineage-determining factor encoding genes RUNX1, SPIB and SPI1 in myelodysplastic syndrome Cheng, J.X.
 2011
 35 S1 p. S14-S15
2 p.
 artikel
278 289 Prognostic evaluation of chronic myelomonocytic leukemia (CMML) with different prognostic models Breccia, M.
 2011
 35 S1 p. S113-S114
2 p.
 artikel
279 320 Prognostic findings in secondary myelodysplastic syndromes/myeloid neoplasms (s-MDS/MN) Tanizawa, R.S.S.
 2011
 35 S1 p. S128-
1 p.
 artikel
280 323 Prognostic impact of cytogenetics in a series of 560 patients with myelodysplastic syndrome in a single institution Waultier, A.
 2011
 35 S1 p. S129-
1 p.
 artikel
281 314 Prognostic impact of cytopenias in MDS – progress beyond the currently used cut-point concept Pfeilstöcker, M.
 2011
 35 S1 p. S125-S126
2 p.
 artikel
282 291 Prognostic impact of JAK2V617F mutation in MDS: a matched case control study de Renzis, B.
 2011
 35 S1 p. S114-
1 p.
 artikel
283 315 Prognostic impact of performance status and comorbidity on the overall survival of patients with myelodysplastic syndromes: A prospective evaluation Ramos, F.
 2011
 35 S1 p. S126-
1 p.
 artikel
284 297 Prognostic impact of severe thrombocytopenia in low risk myelodysplastic syndrome Gonzalez-Porras, J.R.
 2011
 35 S1 p. S117-
1 p.
 artikel
285 18 Prognostic impact of TP53 mutations in MDS with del(5q) Jadersten, M.
 2011
 35 S1 p. S7-
1 p.
 artikel
286 294 Prognostic significance of beta 2 microglobulin in survival and transformation to acute myelogenous leukemia in patients with myelodysplastic syndrome Galanopoulos, A.
 2011
 35 S1 p. S116-
1 p.
 artikel
287 167 Prolonged low-dose azacitidine schedule in high-risk MDS patients: Hematologic and molecular response Finelli, C.
 2011
 35 S1 p. S65-
1 p.
 artikel
288 76 Proteasome proteolytic activity in blood cell populations of MDS patients Karabina, S.
 2011
 35 S1 p. S29-
1 p.
 artikel
289 62 Proteomic screening for plasma autoantibody biomarkers in MDS using protein microarrays Mias, G.I.
 2011
 35 S1 p. S23-
1 p.
 artikel
290 356 Pulmonary embolism combined with heterozygous carrier for factor V Leiden as initial clinical presentation in chronic myelomonocytic leukaemia Gaman, M.
 2011
 35 S1 p. S143-S144
2 p.
 artikel
291 355 5q deletion acquisition was associated with myelodysplastic evolution in patient with essential thrombocythemia JAK2 V617F mutation Assis, R.A.D.
 2011
 35 S1 p. S143-
1 p.
 artikel
292 36 Questions patients with MDS often ask their doctors Steensma, D.P.
 2011
 35 S1 p. S12-S13
2 p.
 artikel
293 16 Recent advances in cytogenetic risk scoring in MDS Haase, D.
 2011
 35 S1 p. S6-S7
2 p.
 artikel
294 72 Refractory Cytopenia with Multilineage Dysplasia (RCMD) patients are related to an abnormal angiogenesis del Rey, M.
 2011
 35 S1 p. S28-
1 p.
 artikel
295 232 Relevance of WT1 expression, mutations and single nucleotide polymorphisms in juvenile myelomonocytic leukemia de Vries, A.
 2011
 35 S1 p. S91-
1 p.
 artikel
296 270 Response to 5-azacitidine in patients with myelodysplastic syndromes and secondary AML: Results from a single hospital De Miguel Llorente, D.
 2011
 35 S1 p. S106-
1 p.
 artikel
297 192 Response to 5-azacytidine in therapy-related malignant neoplasms (t-MN) Voso, M.T.
 2011
 35 S1 p. S76-
1 p.
 artikel
298 67 Response to ESA treatment in patients with MDS: Determination of a predictive score, from a retrospective analysis of 669 patients Symeonidis, A.
 2011
 35 S1 p. S25-
1 p.
 artikel
299 319 Response to treatment with erythropoietin in patients with MDS highly predicts low risk of evolution to AML and longer survival Symeonidis, A.
 2011
 35 S1 p. S127-S128
2 p.
 artikel
300 312 Restratification of IPSS risk groups according to the WPSS identifies patients with myelodysplastic syndromes (MDS) at higher risk Neukirchen, J.
 2011
 35 S1 p. S124-
1 p.
 artikel
301 60 Results of a phase II study of thalidomide (Thai) and azacitidine (Aza) in patients with clinically advanced myelodysplastic syndromes (MDS) Kenealy, M.
 2011
 35 S1 p. S22-
1 p.
 artikel
302 212 Results of single arm, multi-center, two-stage phase II clinical study of thalidomide in Taiwanese patients with myelodysplastic syndrome (MDS) Chang, C.-S.
 2011
 35 S1 p. S83-
1 p.
 artikel
303 225 Retrospective review of treatment of patients with concurrent t-large granular lymphocytosis and myelodysplastic syndrome Tindell, V.
 2011
 35 S1 p. S88-S89
2 p.
 artikel
304 14 Revised International Prognostic Scoring System (IPSS-R), developed by the International Prognostic Working Group for Prognosis in MDS (IWG-PM) Greenberg, P.
 2011
 35 S1 p. S6-
1 p.
 artikel
305 336 α-rHuEPO (40,000 IU twice/week) as single agent in low/intermediate risk myelodysplastic syndromes: A retrospective investigation on 113 patients Azzarà, A.
 2011
 35 S1 p. S134-S135
2 p.
 artikel
306 22 Risk analysis in the treatment of myelodysplastic syndromes in the elderly Kurtin, S.E.
 2011
 35 S1 p. S8-S9
2 p.
 artikel
307 241 Role of inositide signalling regulation in higher-risk MDS patients during epigenetic therapy Follo, M.Y.
 2011
 35 S1 p. S94-S95
2 p.
 artikel
308 234 Role of mitochondrial DNA mutations in childhood MDS de Vries, A.
 2011
 35 S1 p. S92-
1 p.
 artikel
309 166 Safety of panobinostat plus 5-azacitidine in myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia patients: a phase Ib study Fenaux, P.
 2011
 35 S1 p. S65-
1 p.
 artikel
310 79 Selection by severe hypoxia of repopulating progenitor cells in primary MDS bone marrow cell culture Masala, E.
 2011
 35 S1 p. S30-
1 p.
 artikel
311 220 Selective immunosuppression therapy for myelodysplastic syndrome – high response rate and low disease progression Li, X.
 2011
 35 S1 p. S86-
1 p.
 artikel
312 379 Serum hepcidin in patients with myelodysplastic syndrome and primary myelofibrosis Racchi, O.
 2011
 35 S1 p. S151-
1 p.
 artikel
313 372 Serum LDH and ferritin: Improvement of risk assessment in lower risk MDS Azaceta, G.
 2011
 35 S1 p. S148-
1 p.
 artikel
314 164 Severe chronic hepatitis E during the course of secondary AML treated with hypomethylating agent Cougoul, P.
 2011
 35 S1 p. S64-
1 p.
 artikel
315 185 Severe thrombocytopenia but not neutropenia predicts infection complications during azacitidine therapy in high risk MDS patients Ofran, Y.
 2011
 35 S1 p. S73-
1 p.
 artikel
316 210 Should immunosuppressive therapy (1ST) be used more often in lower risk MDS? Cereja, S.
 2011
 35 S1 p. S82-
1 p.
 artikel
317 329 Similar survival between reduced intensity and myeloablative conditioning in MDS patients receiving allogeneic stem cell transplantation Huang, H.H.
 2011
 35 S1 p. S132-
1 p.
 artikel
318 65 Simultaneous analysis of the expression of 14 genes with individual prognostic value in patients with MDS at diagnosis Santamaria, C.
 2011
 35 S1 p. S24-
1 p.
 artikel
319 344 Single centre experience of transfusion-dependent MDS demonstrates a high frequency of allo-antibody formation in heavily transfused patients Milic, M.
 2011
 35 S1 p. S138-
1 p.
 artikel
320 56 Six new prognostic markers determined using gene expression profiling, separate chronic myelomonocytic leukaemia in two distinct subtypes Samra, E. Bou
 2011
 35 S1 p. S20-
1 p.
 artikel
321 122 SNP-A karyotyping in MDS and MDS/MPN cases with normal karyotype Mallo, M.
 2011
 35 S1 p. S47-
1 p.
 artikel
322 108 SNP-A karyotyping in primary myelodysplastic syndromes with unsuccessful routine cytogenetic testing Arenillas, L.
 2011
 35 S1 p. S41-S42
2 p.
 artikel
323 299 SOCS1 methylation and azacitidine response in high risk myelodysplasia (MDS) and secondary acute myeloid leukemia (AML) Prebet, T.
 2011
 35 S1 p. S118-
1 p.
 artikel
324 154 Some determinants of disease specific mortality in MDS Noesslinger, T.
 2011
 35 S1 p. S60-S61
2 p.
 artikel
325 133 Specificity of features of the bone marrow CD34+ cell fraction for the diagnosis of MDS Reis-Alves, S.C.
 2011
 35 S1 p. S51-S52
2 p.
 artikel
326 127 Spectral karyotyping (SKY) reveals a new subset of MDS patients with clonal chromosomal abnormalities not detected by G-banding analysis Oliveira, F.M.
 2011
 35 S1 p. S49-
1 p.
 artikel
327 40 Spontaneous abrogation of a DNA damage checkpoint has clinical benefit but promotes MDS/AML in Fanconi anemia Ceccaldi, R.
 2011
 35 S1 p. S14-
1 p.
 artikel
328 130 SPR chip for MDS diagnosis based on protein-protein interaction Pimkova, K.
 2011
 35 S1 p. S50-
1 p.
 artikel
329 8 Standardization of flow cytometric analysis in myelodysplastic syndromes Porta, M.G. Pella
 2011
 35 S1 p. S3-S4
2 p.
 artikel
330 137 Standardization of flow cytometry in myelodysplastic syndromes: A report from an international consortium and the European LeukemiaNet Working Group Westers, T.M.
 2011
 35 S1 p. S53-
1 p.
 artikel
331 311 STAT signaling alterations in leukemic progenitors can predict the response of myelodysplastic syndrome (MDS) patients to azacytidine Miltiades, P.
 2011
 35 S1 p. S123-S124
2 p.
 artikel
332 88 Study of leukemic transformation and survival in patients with myelodysplastic syndrome (MDS) treated with granulocyte colony-stimulating factor (G-CSF) Diamantopoulos, P.T.
 2011
 35 S1 p. S33-
1 p.
 artikel
333 324 Study on karyotypic abnormalities and its prognostic significance in Chinese patients with primary myelodysplastic syndromes Xiao, Z.
 2011
 35 S1 p. S129-S130
2 p.
 artikel
334 263 Study on NPM1 gene mutations in patients with primary myelodysplastic syndromes Xiao, Z.
 2011
 35 S1 p. S103-
1 p.
 artikel
335 347 Successful treatment of transfusional iron overload in MDS patients with deferasirox as indicated by Liver-MRI: A German, multi-center trial Nolte, F.
 2011
 35 S1 p. S139-
1 p.
 artikel
336 165 Synergistic effects on apoptosis in higher risk MDS by combining azacitidine (AZA) and the EGFR-tyrosine kinase inhibitor erlotinib Elodie, L.
 2011
 35 S1 p. S64-S65
2 p.
 artikel
337 296 Telomere shortening is associated with AML progression in patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide Göhring, G.
 2011
 35 S1 p. S117-
1 p.
 artikel
338 281 Ten years of a prospective haematological survey of patients affected by Shwachman-Diamond syndrome: Results of an Italian multicentric study Sainati, L.
 2011
 35 S1 p. S110-S111
2 p.
 artikel
339 54 Terminal effector memory T cell expansion: Biomarker for lenalidomide resistance in myelodysplastic syndrome Zhang, L.
 2011
 35 S1 p. S19-S20
2 p.
 artikel
340 305 TET2 and IDH1/2 mutations in secondary acute myeloid leukemias: A French retrospective study Kosmider, O.
 2011
 35 S1 p. S120-
1 p.
 artikel
341 322 TET2 mutations, methylation profile and prognosis in higher risk myelodysplastic syndromes (MDS) treated with 5-azacytidine and valproic acid Voso, M.T.
 2011
 35 S1 p. S129-
1 p.
 artikel
342 357 Thalidomide in patients with myelodysplastic syndrome Hayashi, K.
 2011
 35 S1 p. S144-
1 p.
 artikel
343 9 The added value of quality-of-life and other patient-reported outcomes in clinical research of patients with myelodysplastic syndromes Efficace, F.
 2011
 35 S1 p. S4-
1 p.
 artikel
344 43 The broad use of erythropoietic stimulating agents (ESA) for myelodysplastic syndromes (MDS) in the U.S. is not consistent with guidelines Davidoff, A.J.
 2011
 35 S1 p. S15-
1 p.
 artikel
345 259 The clonal advantage of del(5q) MDS stem cells is mediated by increased adhesion to the microenvironment Scharenberg, C.
 2011
 35 S1 p. S101-S102
2 p.
 artikel
346 368 The combination of refractory anaemia with ring sideroblasts (RARS) and T-cell leukemia of large granular lymphocyte (T-LGL) Vinogradova, Y.
 2011
 35 S1 p. S147-
1 p.
 artikel
347 206 The decrease of B lymphocytes in MDS patients; expression of genes and microRNAs in B cell precursors Neuwirtova, R.
 2011
 35 S1 p. S80-S81
2 p.
 artikel
348 188 The EGFR-inhibitor erlotinib sensitizes MDS derived cells to chemotherapeutic agents by increasing their intracellular retention via modulation of ABC-transporters Sebert, M.
 2011
 35 S1 p. S74-
1 p.
 artikel
349 143 The health-related quality of life of MDS patients is impaired and most predicted by transfusion dependence, hemoglobin and age Buckstein, R.
 2011
 35 S1 p. S55-S56
2 p.
 artikel
350 50 The identification of novel somatic mutations in MDS by whole exome sequencing Papaemmanuil, E.
 2011
 35 S1 p. S18-
1 p.
 artikel
351 334 The importance of prognostic parametres for the allogeneic transplantation course in patients with myelodysplastic syndromes and secondary acute leukemia Vondráková, J.
 2011
 35 S1 p. S134-
1 p.
 artikel
352 286 The presence of aberrant myeloid progenitors predicts overall survival in intermediate-2 and high risk myelodysplastic syndromes upon treatment with azacitidine Alhan, C.
 2011
 35 S1 p. S112-
1 p.
 artikel
353 302 The quantity of clonal cells detected by conventional cytogenetics correlates with bone marrow blasts and leukemia free survival in MDS Kim, M.
 2011
 35 S1 p. S119-
1 p.
 artikel
354 303 The quantity of p15INK4B methylation is lower in pediatric MDS than in adults, but correlates with BM blast and survival Kim, M.
 2011
 35 S1 p. S119-S120
2 p.
 artikel
355 103 Therapy-related myeloid neoplasms following treatment with radioiodine Schroeder, T.M.
 2011
 35 S1 p. S39-S40
2 p.
 artikel
356 274 The response of FLi1, EKLF, TP53 (p53), PU.1, MDM2 gene expression in 5q- syndrome to lenalidomide treatment Jonasova, A.
 2011
 35 S1 p. S108-
1 p.
 artikel
357 201 The role of c-Myc and MMPs in the malignant transformation of patients with myelodysplastic syndromes Jiang, G.
 2011
 35 S1 p. S79-
1 p.
 artikel
358 198 The role of cytokine, telomerase activity and apoptosis associated proteins in inefficient hematopoiesis of patients with myelodysplastic syndromes Jiang, G.
 2011
 35 S1 p. S78-
1 p.
 artikel
359 75 The role of osteoblasts in the hematopoietic microenvironment in patients with myelodysplastic syndrome (MDS) Kalyvioti, E.
 2011
 35 S1 p. S28-S29
2 p.
 artikel
360 53 The role of p53 in the cytopenias of NUP98-HOXD13 driven MDS and its progression to acute leukemia Xu, H.
 2011
 35 S1 p. S19-
1 p.
 artikel
361 112 The use of the proportion of CD34+ cells and B-lymphoid progenitors to distinguish subgroups of MDS from non-MDS cytopenic patients Cullen, M.J.
 2011
 35 S1 p. S43-
1 p.
 artikel
362 222 The weight of serum epoetin levels in “good” Hellström-Lindberg prognostic group for erythroid response to erythropoetin treatment Riva, M.
 2011
 35 S1 p. S87-
1 p.
 artikel
363 301 Thrombocytopenia at diagnosis as an important negative prognostic marker in isolated 5q- MDS (IPSS low and Intermediate-1) Jonasova, A.
 2011
 35 S1 p. S119-
1 p.
 artikel
364 5 Thrombomimetic agents in myelodysplastic syndromes Cherif, H.
 2011
 35 S1 p. S2-
1 p.
 artikel
365 213 Thrombotic events in del(5q) associated myelodysplastic syndromes Comont, T.
 2011
 35 S1 p. S83-
1 p.
 artikel
366 51 Transcription Intermediary Factor 1 gamma (TIF1γ) is an epigenetically-regulated tumor suppressor gene in human chronic myelomonocytic leukemia Droin, N.
 2011
 35 S1 p. S18-
1 p.
 artikel
367 345 Transfusion burden of myelodysplastic syndrome in Edmonton, Alberta Arewa, O.
 2011
 35 S1 p. S138-
1 p.
 artikel
368 106 Treatment of advanced CMML by azacitidine (AZA) in a compassionate program. The GFM experience in 38 patients (pts) Wolfromm, A.
 2011
 35 S1 p. S40-
1 p.
 artikel
369 249 Two novel TET2 gene mutations in myelodysplastic syndrome Servillo, P.
 2011
 35 S1 p. S97-S98
2 p.
 artikel
370 177 UK experience of azacitidine therapy in patients with myelodysplastic syndromes Killick, S.
 2011
 35 S1 p. S69-S70
2 p.
 artikel
371 38 Uncoupling of GTP hydrolysis from eIF6 release on the ribosome causes Shwachman-Diamond syndrome Finch, A.J.
 2011
 35 S1 p. S13-
1 p.
 artikel
372 45 Unimpaired terminal erythroid differentiation and preserved enucleation capacity in myelodysplastic 5q(del) clones: A single cell study Garderet, L.
 2011
 35 S1 p. S16-
1 p.
 artikel
373 111 Uniparental disomy (UPD) of P15/INK4 gene is correlated with better hematologic response to azacitidine Cluzeau, T.
 2011
 35 S1 p. S42-S43
2 p.
 artikel
374 119 2011-update and overview of data in the German-Austrian-Suisse MDS registry (D-A-CH MDS registry) Germing, U.
 2011
 35 S1 p. S46-
1 p.
 artikel
375 215 Update of open-label extension study evaluating the long-term safety and efficacy of romiplostim in thrombocytopenic patients with myelodysplastic syndromes (MDS) Fenaux, P.
 2011
 35 S1 p. S84-
1 p.
 artikel
376 136 Using flow cytometry for differential diagnosis of thrombocytopenia Subira, D.
 2011
 35 S1 p. S52-S53
2 p.
 artikel
377 363 Utility of LH750 white cell differential positional parameters as a sensitive screen for myelodysplastic syndrome Sitaram, U.
 2011
 35 S1 p. S145-S146
2 p.
 artikel
378 160 Validation of a disease-specific quality of life questionnaire (QoL-E) for patients with myelodysplastic syndromes (MDS) in Germany von Mackensen, S.
 2011
 35 S1 p. S63-
1 p.
 artikel
379 287 Validation of a flow cytometric scoring system for the prognostication of the myelodysplastic syndromes; A retrospective cohort study Alhan, C.
 2011
 35 S1 p. S113-
1 p.
 artikel
380 325 Validation of the ‘Texas Score’ for the prognostication of patients with myelodysplastic syndromes Zipperer, E.
 2011
 35 S1 p. S130-
1 p.
 artikel
381 295 Validation of the WHO 2008 classification for ‘non-blastic’ myelodysplastic syndromes. Lumping or splitting? Germing, U.
 2011
 35 S1 p. S116-
1 p.
 artikel
382 191 Vorinostat and low dose cytarabine for high risk myelodysplastic syndromes with azacytidine failure: the GFM-VOR2007 study Prebet, T.
 2011
 35 S1 p. S75-S76
2 p.
 artikel
383 Welcome Bowen, David T.
 2011
 35 S1 p. v-
1 p.
 artikel
384 290 WT1 expression level in peripheral blood: an early marker of myelodysplastic syndromes evolution? Bustany, S.
 2011
 35 S1 p. S114-
1 p.
 artikel
385 268 WT1, PR1, and PRAME antigens may be a good combination for immunotherapy in myelodysplastic syndrome Borges Jr, F. Araujo
 2011
 35 S1 p. S105-S106
2 p.
 artikel
                             385 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland